Clinical Trial Search

Primary: Percentage of Participants Achieving Low Disease Activity Score — 100 percentage of participants

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — -17.8; -23.7; -25.5 score on a scale — p=0.070

Primary: Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale — 161; 182 Participants — p=0.1994

Primary: Number of Participants With Incidence of Composite Efficacy Failure — 76; 62; 59; 34 Participants

Primary: Survival — 37; 31 participants

Primary: Double Blind (DB) Phase: Median Time to Relapse — NA; 49.0 Days

Primary: Change From Baseline to Month 12 in Left Ventricular Mass Indexed to Height (LVMI) — 3.2; 0.5; -10.3 g/m^2.7

Primary: Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines — 4.8; 2.5…

Primary: Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks — -0.009; 0.142; 0.156; 0.168 Liter — p=<0.0001

Primary: Hemoglobin — 13.5; 13.3; 13.3; 13.4 g/dL

Primary: Depressive Relapse or MDD — 18; 18.3; 32.7 % patients who relapsed — p=.42

Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) — 0.205; 0.093 Liters — p=<0.001

Primary: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 — 0.15; -0.70; -0.89 Percentage of HbA1c in the blood — p=<0.0001

Primary: Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value) — -0.74; -0.76; 0.29 percent HbA1C

Primary: The Percentage of Patients Achieving Clinical Remission — 25 percentage of patients